The effect of orlistat and metformin in the treatment of fatty liver disease

Compare of orlistat and metformin in the treatment of fatty liver disease in non-diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016031827097N1

Enrollment

100

Registered

2016-06-05

Start date

2016-03-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. nonalcoholic steatohepatitis

Interventions

Intervention 1: Tablet Metformin 1000mg once in a day for 3 mounths. Intervention 2: Tablet Orlistat 120mg once in a day for 3 mounths.

Treatment - Drugs

Tablet Metformin 1000mg once in a day for 3 mounths

Tablet Orlistat 120mg once in a day for 3 mounths

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (Inclusion criteria: Having Nonalcoholic fatty liver disease, the absence of diabetes mellitus, Fatty liver grade 2 and above, not having severe systemic disease, Lack of viral and autoimmune hepatitis, Lack of thyroid disease, do not have hyper triglyceridemia and Exclusion criteria: Having severe systemic disease, having viral hepatitis and autoimmune, having thyroid disease, Hyper triglyceridemia)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Triglyceride of blood. Timepoint: Befor and after the study. Method of measurement: Milligrams per deciliter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Iranparvar

Ardebil University of Medical Sciences

m.iranparvar@arums.ac.ir+98 914 415 0700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026